Kate E. Lawlor

Dr. Kate E. Lawlor


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2005 in Nature
Verified
Journal Article
Closed access
HSHeather Stanton
Heather Stanton
FRFraser M. Rogerson
Fraser M. Rogerson
CECharlotte J. East
Charlotte J. East
SGSuzanne B. Golub
Suzanne B. Golub
KLKate E. Lawlor
Kate E. Lawlor
AFAmanda Fosang
Amanda Fosang

18 February 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
KLKate E. Lawlor
Kate E. Lawlor
NKNufail Khan
Nufail Khan
AMAlison Mildenhall
Alison Mildenhall
MGMotti Gerlic
Motti Gerlic
BCBen A. Croker
Ben A. Croker
JVJames E. Vince
James E. Vince
RIPK3 and its substrate MLKL are essential for necroptosis, a lytic cell death proposed to cause inflammation via the release of intracellular molecules. Whether and how RIPK3 might drive inflammation in a manner independent of MLKL and cell lysis remains unclear. Here we show that following LPS treatment, or LPS-induced necroptosis, the TLR adaptor protein TRIF and inhibitor of apoptosis proteins (IAPs: X-linked IAP, cellular IAP1 and IAP2) regulate RIPK3 and MLKL ubiquitylation. Hence, when IAPs are absent, LPS triggers RIPK3 to activate caspase-8, promoting apoptosis and NLRP3–caspase-1 activation, independent of RIPK3 kinase activity and MLKL. In contrast, in the absence of both IAPs and caspase-8, RIPK3 kinase activity and MLKL are essential for TLR-induced NLRP3 activation. Consistent with in vitro experiments, interleukin-1 (IL-1)-dependent autoantibody-mediated arthritis is exacerbated in mice lacking IAPs, and is reduced by deletion of RIPK3, but not MLKL. Therefore RIPK3 can promote NLRP3 inflammasome and IL-1β inflammatory responses independent of MLKL and necroptotic cell death.

1 May 2014 in Cell
Verified
Journal Article
Closed access
JRJames A. Rickard
James A. Rickard
JOJoanne A. O’donnell
Joanne A. O’donnell
JEJoseph M. Evans
Joseph M. Evans
NLNajoua Lalaoui
Najoua Lalaoui
APAshleigh Poh
Ashleigh Poh
JSJohn Silke
John Silke

1 April 2020 in Cell Reports
Verified
Journal Article
Open access
KBKatherine R. Balka
Katherine R. Balka
CLCynthia Louis
Cynthia Louis
TSTahnee L. Saunders
Tahnee L. Saunders
ASAmber M. Smith
Amber M. Smith
DCDale J. Calleja
Dale J. Calleja
Dominic De NardoDominic De Nardo
Dominic De Nardo
Stimulator of Interferon Genes (STING) is a critical component of host innate immune defense but can contribute to chronic autoimmune or autoinflammatory disease. Once activated, the cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) (cGAMP) synthase (cGAS)-STING pathway induces both type I interferon (IFN) expression and nuclear factor-κB (NF-κB)-mediated cytokine production. Currently, these two signaling arms are thought to be mediated by a single upstream kinase, TANK-binding kinase 1 (TBK1). Here, using genetic and pharmacological approaches, we show that TBK1 alone is dispensable for STING-induced NF-κB responses in human and mouse immune cells, as well as in vivo. We further demonstrate that TBK1 acts redundantly with IκB kinase ε (IKKε) to drive NF-κB upon STING activation. Interestingly, we show that activation of IFN regulatory factor 3 (IRF3) is highly dependent on TBK1 kinase activity, whereas NF-κB is significantly less sensitive to TBK1/IKKε kinase inhibition. Our work redefines signaling events downstream of cGAS-STING. Our findings further suggest that cGAS-STING will need to be targeted directly to effectively ameliorate the inflammation underpinning disorders associated with STING hyperactivity.

1 February 2012 in Immunity
Verified
Journal Article
Closed access
JVJames E. Vince
James E. Vince
Wendy WongWendy Wong
Wendy Wong
IGIan Gentle
Ian Gentle
KLKate E. Lawlor
Kate E. Lawlor
RARamanjaneyulu Allam
Ramanjaneyulu Allam
JTJürg Tschopp
Jürg Tschopp

17 January 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SCStephanie A. Conos
Stephanie A. Conos
KCKaiwen W. Chen
Kaiwen W. Chen
Dominic De NardoDominic De Nardo
Dominic De Nardo
HHHideki Hara
Hideki Hara
LWLachlan Whitehead
Lachlan Whitehead
JVJames E. Vince
James E. Vince
Necroptosis is a physiological cell suicide mechanism initiated by receptor-interacting protein kinase-3 (RIPK3) phosphorylation of mixed-lineage kinase domain-like protein (MLKL), which results in disruption of the plasma membrane. Necroptotic cell lysis, and resultant release of proinflammatory mediators, is thought to cause inflammation in necroptotic disease models. However, we previously showed that MLKL signaling can also promote inflammation by activating the nucleotide-binding oligomerization domain (NOD)-like receptor protein 3 (NLRP3) inflammasome to recruit the adaptor protein apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC) and trigger caspase-1 processing of the proinflammatory cytokine IL-1β. Here, we provide evidence that MLKL-induced activation of NLRP3 requires (i) the death effector four-helical bundle of MLKL, (ii) oligomerization and association of MLKL with cellular membranes, and (iii) a reduction in intracellular potassium concentration. Although genetic or pharmacological targeting of NLRP3 or caspase-1 prevented MLKL-induced IL-1β secretion, they did not prevent necroptotic cell death. Gasdermin D (GSDMD), the pore-forming caspase-1 substrate required for efficient NLRP3-triggered pyroptosis and IL-1β release, was not essential for MLKL-dependent death or IL-1β secretion. Imaging of MLKL-dependent ASC speck formation demonstrated that necroptotic stimuli activate NLRP3 cell-intrinsically, indicating that MLKL-induced NLRP3 inflammasome formation and IL-1β cleavage occur before cell lysis. Furthermore, we show that necroptotic activation of NLRP3, but not necroptotic cell death alone, is necessary for the activation of NF-κB in healthy bystander cells. Collectively, these results demonstrate the potential importance of NLRP3 inflammasome activity as a driving force for inflammation in MLKL-dependent diseases.